Hans Will

TL;DR: Giovanni Raimondo*, Jean-Pierre Allain, Maurizia R. Brunetto, Marie-Annick Buendia, Ding-Shinn Chen, Massimo Colombo, Antonio Craxi, Francesco Donato, Carlo Ferrari, Giovanni B. Gaeta, Wolfram H. Gerlich,Massimo Levrero, Stephen Locarnini, Thomas Michalak, Mario U. Zanetti, Fabien Zoulim

TL;DR: It is demonstrated that the human serine/threonine kinase homeodomain-interacting protein kinase-2 colocalizes and interacts with p53 and CREB-binding protein (CBP) within promyelocytic leukaemia (PML) nuclear bodies and implies that HIPK2 is a novel regulator of p53 effector functions involved in cell growth, proliferation and apoptosis.

TL;DR: It is suggested that HBV genomes with C gene deletions can have a selective advantage in immunosuppressed patients and the potential for the structural and functional characterization of heterogeneous populations of complete virion-encapsidated HBV DNAs is demonstrated.

TL;DR: Partial repopulation of the liver of immunodeficient urokinase‐type plasminogen activator (uPA)/recombinant activation gene‐2 (RAG‐2) mice with normal human hepatocytes isolated from the adult liver is reported, providing proof that normalhuman hepatocytes can integrate into the mouse hepatic parenchyma, undergo multiple cell divisions, and remain permissive for a human hepatotropic virus in a xenogenic liver.

TL;DR: The results indicate the existence of a cross‐talk between PML‐ and p53‐dependent growth suppression pathways, implying an important role for NBs and their resident proteins as modulators of p53 functions.